Alan F. Denenberg

Davis Polk advised McKesson Corporation in connection with the offer by McKesson to exchange shares of McKesson common stock for shares of PF2 SpinCo, Inc. (“SpinCo”) common stock owned by…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due…

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Citrix Systems, Inc. of $750 million aggregate principal amount of its 3.300% senior notes due 2030…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised Shockwave Medical, Inc. in connection with a $16.5 million supplemental term loan provided by Silicon Valley Bank. Shockwave Medical used a portion of the proceeds…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion SEC-registered debt offering by Intel Corporation. The offering consisted of $750 million…